News & Updates

Empagliflozin significantly reduces hepatic fat content vs placebo in patients with metabolic dysfunction–associated steatotic liver disease (MASLD) without diabetes, researchers from the University of Hong Kong have reported.

A novel artificial intelligence (AI) classifier can detect hepatocellular carcinoma (HCC) signatures in routine blood tests up to 1 year before clinical diagnosis, as shown in a study from Hong Kong.

A recent study has noted the excellent specificity and negative predictive value of FIB-4 and nonalcoholic fatty liver disease (NAFLD) fibrosis score (NFS) in diagnosing advanced fibrosis (AF, bridging fibrosis or cirrhosis) among people living with HIV (PWH).

The presence of jaundice or fluid retention among patients with hepatocellular carcinoma (HCC) is associated with a shorter overall survival (OS), suggests a Singapore study.

The incidence of cirrhosis and hepatocellular carcinoma (HCC) among veterans differs according to demographic and clinical characteristics, with the lowest rate seen among Asians, reports a study.

A phase II trial of cabozantinib demonstrates the study drug’s efficacy in patients with hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitor (ICI) regimens.

Use of ticagrelor compared with clopidogrel contributes to a similar risk of major adverse cardiovascular events (MACE) and a higher risk of major bleeding in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI), reveals a study.